P3 Health Partners (NASDAQ:PIII) versus Biotricity (OTCMKTS:BTCY) Head to Head Comparison

Biotricity (OTCMKTS:BTCY) and P3 Health Partners (NASDAQ:PIII) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, dividends, risk, profitability, analyst recommendations and institutional ownership.

Profitability

This table compares Biotricity and P3 Health Partners’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Biotricity	-37.33%	N/A	-94.07%
P3 Health Partners	-9.99%	-183.60%	-17.83%

Institutional & Insider Ownership

3.9% of Biotricity shares are held by institutional investors. Comparatively, 7.8% of P3 Health Partners shares are held by institutional investors. 10.1% of Biotricity shares are held by insiders. Comparatively, 17.8% of P3 Health Partners shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Volatility & Risk

Biotricity has a beta of 1.19, indicating that its stock price is 19% more volatile than the S&P 500. Comparatively, P3 Health Partners has a beta of 0.82, indicating that its stock price is 18% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations for Biotricity and P3 Health Partners, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biotricity	0	0	0	0	0.00
P3 Health Partners	0	1	1	0	2.50

P3 Health Partners has a consensus target price of $16.25, indicating a potential upside of 88.95%. Given P3 Health Partners’ stronger consensus rating and higher possible upside, analysts plainly believe P3 Health Partners is more favorable than Biotricity.

Earnings and Valuation

This table compares Biotricity and P3 Health Partners”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biotricity	$12.06 million	1.50	-$8.42 million	($0.21)	-3.45
P3 Health Partners	$1.50 billion	0.04	-$135.85 million	($46.01)	-0.19

Biotricity has higher earnings, but lower revenue than P3 Health Partners. Biotricity is trading at a lower price-to-earnings ratio than P3 Health Partners, indicating that it is currently the more affordable of the two stocks.

Summary

P3 Health Partners beats Biotricity on 9 of the 14 factors compared between the two stocks.

About Biotricity

Biotricity, Inc., a medical technology company, provides biometric data monitoring solutions in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It offers Bioflux mobile cardiac telemetry solution, an integrated ECG device; and ECG analysis software that analyzes and synthesizes patient ECG monitoring data, as well as software components. The company is based in Redwood City, California.

About P3 Health Partners

P3 Health Partners Inc., a patient-centered and physician-led population health management company, provides superior care services in the United States. It operates clinics and wellness centers. P3 Health Partners Inc. was founded in 2020 and is based in Henderson, Nevada.